Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings

Abstract

Disclosures of conflicts of interest at drug advisory committee meetings are common, often of considerable monetary value, and rarely result in recusal of advisory committee members. A weak relationship between certain types of conflicts and voting behaviors was detected, but excluding advisory committee members and voting consultants with conflicts would not have altered the overall vote outcome at any meeting studied.

South African Guidelines Excellence (SAGE): Clinical practice guidelines - quality and credibility

“…Funding for the CPG and endorsements should be stated clearly. [12] Independence is essential when sourcing and critiquing the evidence, so that one person's or group's view of the literature does not dominate. [13] Underlying evidence.…”

Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals

“…Furthermore, exclusion of "conflicted" advisory committee members would not have changed the overall vote outcome at any meeting they studied. 134 These findings confirm that physicians and medical scientists can provide objective, evidence-based reasoning even if supported by industry. At least in some cases, the same cannot be said when the tort bar, consultants to plaintiffs' attorneys, and medical publication mix.…”

Pharmacy and Therapeutics Committees: Leadership Opportunities in Medication Safety for Medical Toxicologists

“…A critical issue in medicine, nationally and affecting formulary policy, is the pharmaceutical industry influence on practitioners [13]. A team of specialists, for example, may be persuaded to use a new drug that has been newly marketed and detailed to them either locally or nationally at a professional meeting.…”